Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of MacroGenics's Vobramitamab Duocarmazine?
Vobramitamab Duocarmazine is a monoclonal antibody conjugated commercialized by MacroGenics, with a leading Phase II program in Melanoma. According to...
Data Insights
Risk adjusted net present value: What is the current valuation of MacroGenics's Vobramitamab Duocarmazine?
Vobramitamab Duocarmazine is a monoclonal antibody conjugated commercialized by MacroGenics, with a leading Phase II program in Anal Cancer. According...